ArticleAntimicrobial agents and chemotherapy2008
In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba.
Article in Antimicrobial agents and chemotherapy, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 67 citations in OpenAlex.
- A phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasis.Antimicrobial agents and chemotherapy · 2015Trial
- Effect of mild and moderate liver disease on the pharmacokinetics of isavuconazole after intravenous and oral administration of a single dose of the prodrug BAL8557.Antimicrobial agents and chemotherapy · 2009Trial
- Antifungal Resistance in Cryptococcal Infections.Pathogens (Basel, Switzerland) · 2024Review
- Comparison between EUCAST Broth Microdilution and MIC Strip Test in Defining Isavuconazole In Vitro Susceptibility againstAntibiotics (Basel, Switzerland) · 2023Article
- Pharmacokinetics of isavuconazole in healthy cats after oral and intravenous administration.Journal of veterinary internal medicine · 2022Article
- In Silico Structural Modeling and Analysis of Interactions ofInternational journal of molecular sciences · 2021Article
- Article
- The status of cryptococcosis in Latin America.Memorias do Instituto Oswaldo Cruz · 2018Review
- Molecular characterisation and antifungal susceptibility of clinical Cryptococcus deuterogattii (AFLP6/VGII) isolates from Southern Brazil.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2016Article
- Hot topics in antifungal susceptibility testing: A new drug, a bad bug, sweeping caspofungin testing under the rug, and solving the ECV shrug.Clinical microbiology newsletter · 2016Article
- Role of isavuconazole in the treatment of invasive fungal infections.Therapeutics and clinical risk management · 2016Review
- Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model.Antimicrobial agents and chemotherapy · 2015Article
- Article
- Isavuconazole therapy protects immunosuppressed mice from mucormycosis.Antimicrobial agents and chemotherapy · 2014Article
- Cryptococcosis: epidemiology, fungal resistance, and new alternatives for treatment.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2013Review
- Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections.Infection and drug resistance · 2013Review
- In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds.Journal of clinical microbiology · 2013Article
- In vitro antifungal activity of isavuconazole against Madurella mycetomatis.Antimicrobial agents and chemotherapy · 2012Article
- Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole.Antimicrobial agents and chemotherapy · 2012Article
- Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for amphotericin B and flucytosine.Antimicrobial agents and chemotherapy · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cuban Cryptococcus isolates (n = 165) were tested in vitro against amphotericin B, flucytosine, fluconazole, itraconazole, voriconazole, posaconazole, and isavuconazole, giving MIC90 values of 0.25, 8, 4, 0.25, 0.125, 0.016, and 0.016 microg/ml, respectively. Isavuconazole and posaconazole seem to be potentially active drugs for treating cryptococcal infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.